Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate

British Journal of Clinical Pharmacology

Volumn 42, Issue 2, 1996, Pages 201-205

  Koch, K M ^a   Davis, I M ^a   Gooding, A E ^a   Yin, Y ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Bismuth; Pharmacokinetics; Ranitidine

Indexed keywords

BISMUTH; RANITIDINE; RANITIDINE BISMUTH CITRATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERANCE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0030036533     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03929.x     Document Type: Article

References (22)

1. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322: 909-916.
2. Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. Ann Intern Med 1991; 115: 266-269.
3. Logan RPH, Gummett PA, Misiewicz JJ, et al. The efficacy of ranitidine bismuth citrate (GR122311X) in the treatment of Helicobacter pylori infection. Gastroenterology 1992; 102 (4, Part 2): A114.
4. 2-antagonist activity, on 24-hour intragastric acidity. Aliment Pharmacol Ther 1991; 5: 481-490.
5. Tytgat GNJ. Colloidal bismuth subcitrate in peptic ulcer - a review. Digestion 1987; 37: 31-41.
6. Konturek SJ, Radecki T, Tiastucki I, Diozdowicz D. Gastrocytoprotection by colloidal bismuth subcitrate (DeNol) and sucralfate. Role of endogenous prostaglandins. Gut 1987; 28: 201-205.
7. Roost R, Wright JP, Young GO, et al. The effect of aspirin and anti-ulcer drugs on gastric mucosal prostaglandin E. S Afr Med J 1986; 70: 594-597.
8. Hudson N, Murray FE, Cole AT, Turnbull GM, Lettis S, Hawkey CJ. Ranitidine bismuth citrate and aspirin-induced gastric mucosal injury. Aliment Pharmacol Ther 1993; 7: 515-521.
9. Stables R, Campbell CJ, Clayton NM, Clitherow JW, Grinham CJ, McColm AA. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment Pharmacol Ther 1993; 7: 237-246.
10. Grant SM, Langtry HD, Brogden RN. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989; 37: 801-870.
11. Froomes PRA, Wan AT, Keech AC, McNeil JJ, McLean AJ. Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate. Eur J Clin Pharmacol 1989; 37: 533-536.
12. Lacey LF, Frazer NM, Keene ON, Smith JTL. Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). Eur J Clin Pharmacol 1994; 47: 177-180.
13. Benet LZ. Safety and pharmacokinetics: Colloidal bismuth subcitrate. Scand J Gastroenterol 1991; 26: 29-35.
14. Wormsley KG. Safety profile of ranitidine. A review. Drugs 1993; 46: 976-985.
15. Hillemand P, Pallierer M, Laquais B, Bouvet P. Traitement bismuthique et bismuthemie. Semin Hop Paris 1977; 53: 1663-1669.
16. Lloyd TL, Perschy TB, Gooding AE, Tomlinson JJ. Robotic solid phase extraction and high performance liquid chromatographic analysis of ranitidine in serum or plasma. Biomed Chromatog 1992; 6: 311-316.
17. DA Tye, DD Tye, R Brown, IM Davis. Sensitive determination of bismuth concentrations in human plasma, blood and urine using inductively coupled plasma mass spectrometry. Pharm Res 1992; 9: S-15.
18. 2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterol 1991; 101: 889-894.
19. Rao N, Feldman S. Disposition of bismuth in the rat. I. Red blood cell and plasma protein binding. Pharm Res 1990; 7: 188-191.
20. McLean AJ, Froomes PRA, Wan AT. Biliary handling of bismuth subcitrate in man. Clin Pharmacol Ther 1989; 45: 150.
21. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36: 132-157.
22. Gorbach SL. Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990; 99: 863-875.